Heron Therapeutics, Inc.

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
3.5 ^USD	-4.63%		+15.13%	+105.88%

07-15	Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs	MT
07-15	Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System	CI

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to NASDAQ Composite Index

January 24, 2014 at 05:00 am

Heron Therapeutics, Inc. will be added to the NASDAQ Composite Index.

Latest news about Heron Therapeutics, Inc.

Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs	07-15	MT
Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System	07-15	CI
Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle	07-02	MT
Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle	07-02	CI
Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to S&P Biotechnology Select Industry Index	06-23	CI
Connect Biopharma Names New Chief Executive, Chair	06-12	MT
Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle	05-29	MT
Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")	05-29	CI
Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day	05-15
Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	05-07	CI
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	04-23	MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	03-21	CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	03-13	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	03-13	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	03-13	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	03-13	MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	03-12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	03-12	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	01-24	DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	01-24	MT

Chart Heron Therapeutics, Inc.

Duration

Period

More charts

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Sector

Biotechnology & Medical Research

Calendar

04/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Heron Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.5 USD

Average target price

6.75 USD

Spread / Average Target

+92.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HERON THERAPEUTICS, INC.	+105.88%	553M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research